NCT03771313View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

November 30, 2024

Study Completion Date

July 31, 2025

Conditions
Cystic Fibrosis
Interventions
DRUG

Ceftaroline

Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.

Trial Locations (1)

42229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03771313 - Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis | Biotech Hunter | Biotech Hunter